186 Results From a 12-Month Open-label Safety Study of Lumateperone (ITI-007) in Patients with Stabl...
186 Results From a 12-Month Open-label Safety Study of Lumateperone (ITI-007) in Patients with Stable Symptoms of Schizophrenia
About this item
Full title
Author / Creator
Publisher
United States: Cambridge University Press
Journal title
Language
English
Formats
Publication information
Publisher
United States: Cambridge University Press
Subjects
More information
Scope and Contents
Contents
Lumateperone (lumateperone tosylate, ITI-007) is an investigational drug for the treatment of schizophrenia, bipolar depression, and other disorders. Lumateperone has a unique mechanism of action that simultaneously modulates serotonin, dopamine, and glutamate neurotransmission. This may provide advantages in the treatment of the broad symptoms ass...
Alternative Titles
Full title
186 Results From a 12-Month Open-label Safety Study of Lumateperone (ITI-007) in Patients with Stable Symptoms of Schizophrenia
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2754969208
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2754969208
Other Identifiers
ISSN
1092-8529
E-ISSN
2165-6509
DOI
10.1017/S1092852920001017
